Rigel Pharmaceuticals, Inc (RIGL) Fair Value & Analysis
Healthcare · US · Market cap $661M
Rigel Pharmaceuticals, Inc
RIGL · US
Fair value as of: Jul 18, 2026
From 23 valuation models · updated today
Share price +21.5% over the past month.
Price vs Fair Value (12 months)
12‑month range $18.80 – $50.96 · fair‑value band $71.89 – $224.67 · the $40.54 price screens below the $120.66 fair value. As of Jul 18, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Rigel Pharmaceuticals, Inc (RIGL) currently trades at $40.54, while our model-based Fair Value estimate is $120.66, implying the stock looks roughly 197.6% undervalued today. We read business quality at 65/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Trailing-twelve-month revenue stands at $300M. Revenue grew 10.3% year over year. It earns a return on equity of 174.1%. Net debt stands at $12.7M. Fundamentals as of Jul 18, 2026
Our scenario range runs from $71.89 (bear case) to $224.67 (bull case); at $40.54, the current price sits below that range. The share trades about 22% below its 52-week high and 123% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -23% fair-value upside, at 198%, RIGL screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 18, 2026. TTM = trailing twelve months.
About the company
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Rigel Pharmaceuticals, Inc reported revenue of $294M in FY2025 versus $149M in FY2021, a compound +18.5%/yr. Reported net income was $367M in FY2025.
Is RIGL fairly valued? → Check now
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 18, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $435.71 | $314.53 | -28% |
| Regeneron Pharmaceuticals, Inc REGN | $664.45 | $594.40 | -11% |
| UCB SA UCB | €274.90 | €211.40 | -23% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,011,109 KRW | +1% |
| CSL Limited CSL | A$116.32 | A$126.60 | +9% |
| Celltrion, Inc 068270 | 167,300 KRW | 76,382 KRW | -54% |
| BioNTech SE B1NT34 | R$29.19 | R$21.38 | -27% |
| WuXi Biologics (Cayman) Inc 2269 | HK$30.74 | HK$28.99 | -6% |
| Innovent Biologics, Inc 1801 | HK$85.35 | HK$21.13 | -75% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Rigel Pharmaceuticals, Inc (RIGL) undervalued?
What is the fair value of RIGL?
What is the quality score of RIGL?
What is the revenue of Rigel Pharmaceuticals, Inc (RIGL)?
What is the net profit margin of RIGL?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Tell me when Rigel Pharmaceuticals, Inc reaches its Fair Value
Just your email, and we'll notify you when the price and Fair Value of Rigel Pharmaceuticals, Inc materially change. Free bonus: the monthly Top-25 report of the most undervalued quality stocks.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.